Skip to main navigation

Who We Are

Leadership team
How we work
Work with us

Our Therapies

Technology

Our Pipeline
& Partners

Urogen - Corp Menu Right

Investors & Media

Connect

Funding requests

Privacy policy | Terms of use

Explore

Investors

UroGen Pharma

UroGen Pharma

Investors

Urogen - Investor Relations

Overview

News Releases

Events & Presentations

Financials

Governance

Stock Information

Annual Report & Proxy

Resources

News Releases

News Releases

Year

Feb 15, 2023

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer

--In a Small Feasibility Study, UGN-102 Achieves a Complete Response in 75% (6 of 8) Patients --UGN-102 is Being Studied in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 15, 2023-- UroGen Pharma Ltd.

Read More

Jan 11, 2023

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 11, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from the first and largest post-commercial utilization

Read More

Pagination

First page
Previous page
Page 1
Current page 2

Urogen - Tools

Print Page
Email Alerts
RSS Feeds

Follow us on

Privacy Policy
Terms of Use

© UroGen Pharma, Inc. All rights reserved.